Future research directions should include in vitro and in vivo studies to verify the mechanistic contributions of MOCS2, USP39, SMYD2, GFPT1, and PRKRIR to metabolic reprogramming and immune modulation in SCLC. The gene discussed is USP39; the disease is small cell lung carcinoma.